Evidence map›Paper›PMID 32803474›Full record

ReviewCurrent oncology reports2020

The Changing Landscape of Lymphoma Associated with HIV Infection.

Kai Hübel

Erratum issuedOpen access · hybridAbstract readReview
In one paragraph

Review in Current oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. A Single Centre Retrospective Cohort Analysis of HIV Associated Lymphoma from Northern India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Kai HübelFaculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. kai.huebel@uni-koeln.de.
University Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewCancer remains a major cause of morbidity and mortality in HIV-infected individuals, with aggressive non-Hodgkin's lymphoma as the most frequent one. However, the introduction of modern antiretroviral therapy (ART) drastically improved treatment options and prognosis in HIV-associated lymphomas. This review summarized the current treatment landscape and future challenges in HIV-positive patients with non-Hodgkin's and Hodgkin's lymphoma. RECENT

findingsSelecting the appropriate therapy for the individual patient, diffuse-large B cell lymphoma, Burkitt's lymphoma, and Hodgkin's disease may be curable diseases. In contrast, the prognosis of plasmablastic lymphoma and primary effusion lymphoma remain poor. New treatment approaches, as targeted therapies or CAR T cell therapy, may broaden the therapeutic armamentarium. The continuous application of ART is mandatory for successful treatment. The choice of lymphoma therapy may follow the recommendations for HIV-negative patients, but prospective trials in HIV-lymphoma are needed.

Indexed as

Anti-HIV AgentsBurkitt LymphomaHIV InfectionsHodgkin DiseaseHumansImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinPrognosisAnti-HIV AgentsAntiretroviral therapyHIV lymphomaPathogenesisRisk factorsTreatment

Identifiers

PMID32803474
PMCPMC8302507
OpenAlexW3049540666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.